Merus Announces Financial Results for the Second Quarter 2025 and Provides Business UpdateGlobeNewsWire • 08/05/25
Merus Global Investments Strengthens Leadership and Expands Talent Bench with Strategic Hires and Key PromotionsBusiness Wire • 07/23/25
MRUS Stock Soars 30% in 3 Months After Phase II Cancer Study SuccessZacks Investment Research • 07/11/25
One of Finland's largest energy storage facilities commissioned in Lappeenranta – Merus Power's EUR 15 million delivery completedGlobeNewsWire • 07/03/25
Merus Skyrockets On 'Unprecedented' Cancer Results, Slamming Bicara TherapeuticsInvestors Business Daily • 05/23/25
Merus' Petosemtamab with Pembrolizumab Interim Data Demonstrates Robust Efficacy and Durability in 1L PD-L1+ r/m HNSCCGlobeNewsWire • 05/22/25
Merus Announces Financial Results for the First Quarter 2025 and Provides Business UpdateGlobeNewsWire • 05/07/25
Earnings Preview: Merus N.V. (MRUS) Q1 Earnings Expected to DeclineZacks Investment Research • 05/07/25
Merus Announces Abstract Accepted for Presentation at the 2025 ASCO® Annual MeetingGlobeNewsWire • 04/23/25
Merus to Participate in a Fireside Chat at the 24th Annual Needham Virtual Healthcare ConferenceGlobeNewsWire • 04/01/25
Merus Announces Financial Results for the Fourth Quarter and Full Year 2024 and Provides Business UpdateGlobeNewsWire • 02/27/25
Petosemtamab granted Breakthrough Therapy designation by the U.S. FDA for 1L PD-L1 positive head and neck squamous cell carcinomaGlobeNewsWire • 02/18/25
New England Journal of Medicine Publishes: Efficacy of Zenocutuzumab in NRG1 Fusion-Positive CancerGlobeNewsWire • 02/05/25